These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 2001545)

  • 1. Stimulation of tumor cell growth by vasoactive intestinal peptide.
    Scholar EM; Paul S
    Cancer; 1991 Mar; 67(6):1561-4. PubMed ID: 2001545
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vasoactive intestinal peptide stimulates the growth of rat hepatoma cells in vitro.
    Huang X; Zhang Y; Bu Y; Su H
    Chin Med Sci J; 1993 Sep; 8(3):147-50. PubMed ID: 8142629
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A vasoactive intestinal peptide antagonist inhibits non-small cell lung cancer growth.
    Moody TW; Zia F; Draoui M; Brenneman DE; Fridkin M; Davidson A; Gozes I
    Proc Natl Acad Sci U S A; 1993 May; 90(10):4345-9. PubMed ID: 8389448
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro and in vivo treatment of colon cancer by VIP antagonists.
    Levy A; Gal R; Granoth R; Dreznik Z; Fridkin M; Gozes I
    Regul Pept; 2002 Nov; 109(1-3):127-33. PubMed ID: 12409224
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A lipophilic vasoactive intestinal peptide analog enhances the antiproliferative effect of chemotherapeutic agents on cancer cell lines.
    Gelber E; Granoth R; Fridkin M; Dreznik Z; Brenneman DE; Moody TW; Gozes I
    Cancer; 2001 Oct; 92(8):2172-80. PubMed ID: 11596035
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The autocrine regulatory effect of vasoactive intestinal peptide on the growth of human pancreatic carcinoma cells.
    Chen Y; Chen Q; Lu G; Fan Z; Zhong S
    Chin Med Sci J; 1994 Dec; 9(4):215-9. PubMed ID: 7718859
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vasoactive intestinal peptide (VIP) stimulates in vitro growth of VIP-1 receptor-bearing human pancreatic adenocarcinoma-derived cells.
    Jiang S; Kopras E; McMichael M; Bell RH; Ulrich CD
    Cancer Res; 1997 Apr; 57(8):1475-80. PubMed ID: 9108448
    [TBL] [Abstract][Full Text] [Related]  

  • 8. VIP receptor antagonists and chemotherapeutic drugs inhibit the growth of breast cancer cells.
    Moody TW; Leyton J; Chan D; Brenneman DC; Fridkin M; Gelber E; Levy A; Gozes I
    Breast Cancer Res Treat; 2001 Jul; 68(1):55-64. PubMed ID: 11678309
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of the vasoactive intestinal peptide (VIP) and related peptides on glioblastoma cell growth in vitro.
    Dufes C; Alleaume C; Montoni A; Olivier JC; Muller JM
    J Mol Neurosci; 2003; 21(2):91-102. PubMed ID: 14593209
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of vasoactive intestinal peptide on adenosine 3',5'-monophosphate, ornithine decarboxylase, and cell growth in a human colon cell line.
    Yu D; Seitz PK; Selvanayagam P; Rajaraman S; Townsend CM; Cooper CW
    Endocrinology; 1992 Sep; 131(3):1188-94. PubMed ID: 1324153
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Breast cancer growth is inhibited by vasoactive intestinal peptide (VIP) hybrid, a synthetic VIP receptor antagonist.
    Zia H; Hida T; Jakowlew S; Birrer M; Gozes Y; Reubi JC; Fridkin M; Gozes I; Moody TW
    Cancer Res; 1996 Aug; 56(15):3486-9. PubMed ID: 8758916
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vasoactive intestinal polypeptide stimulates the proliferation of HaCaT cell via TGF-alpha.
    Sung KJ; Chang SE; Paik EM; Lee MW; Choi JH
    Neuropeptides; 1999 Dec; 33(6):435-46. PubMed ID: 10657522
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vasoactive intestinal peptide: a potent stimulator of adenosine 3':5'-cyclic monophosphate accumulation in gut carcinoma cell lines in culture.
    Laburthe M; Rousset M; Boissard C; Chevalier G; Zweibaum A; Rosselin G
    Proc Natl Acad Sci U S A; 1978 Jun; 75(6):2772-5. PubMed ID: 208077
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of functional receptors for vasoactive intestinal peptide and neurotensin in the human submandibular gland duct cell line, HSG-PA.
    Turner JT; Yu H
    Regul Pept; 1991 Oct; 36(2):173-82. PubMed ID: 1666687
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vasoactive intestinal peptide stimulation of human trabecular meshwork cell growth.
    Koh SW; Yeh TH; Morris SM; Leffler M; Higginbotham EJ; Brenneman DE; Yue BY
    Invest Ophthalmol Vis Sci; 1997 Dec; 38(13):2781-9. PubMed ID: 9418731
    [TBL] [Abstract][Full Text] [Related]  

  • 16. (Stearyl, Norleucine17)VIP hybrid antagonizes VIP receptors on non-small cell lung cancer cells.
    Moody TW; Leyton J; Coelho T; Jakowlew S; Takahashi K; Jameison F; Koh M; Fridkin M; Gozes I; Knight M
    Life Sci; 1997; 61(17):1657-66. PubMed ID: 9363981
    [TBL] [Abstract][Full Text] [Related]  

  • 17. VIP inhibits the proliferation of small-cell and nonsmall-cell lung carcinoma.
    Maruno K; Said SI
    Ann N Y Acad Sci; 1996 Dec; 805():389-92; discussion 392-3. PubMed ID: 8993419
    [No Abstract]   [Full Text] [Related]  

  • 18. Vasoactive intestinal peptide inhibits the growth of hamster pancreatic cancer but not human pancreatic cancer in vivo.
    Poston GJ; Yao CZ; Upp JR; Alexander RW; Townsend CM; Thompson JC
    Pancreas; 1988; 3(4):439-43. PubMed ID: 3174607
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vasoactive intestinal peptide potentiates sexual behavior: inhibition by novel antagonist.
    Gozes I; Meltzer E; Rubinrout S; Brenneman DE; Fridkin M
    Endocrinology; 1989 Dec; 125(6):2945-9. PubMed ID: 2583049
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Promotion of differentiation in human colon carcinoma cells by vasoactive intestinal polypeptide.
    Hoosein NM; Black BE; Brattain DE; Brattain MG
    Regul Pept; 1989 Jan; 24(1):15-26. PubMed ID: 2544928
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.